Login to Your Account



Immunovaccine reports success protecting animals from Ebola

By Michael Fitzhugh
Staff Writer

Monday, August 25, 2014
Shares of Immunovaccine Inc. (TSX:V:IMV) gained 14.4 percent Monday, to close at C$1.11 (US$1.01), after the Halifax, Nova Scotia-based company reported that monkeys dosed with an Ebola vaccine employing its Depovax formulation technology survived exposure to a lethal dose of the virus in a challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription